Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs NEOPHAM 6.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
NEOPHAM 6.4% is a sterile, nonpyrogenic, hypertonic solution of amino acids and glycerin used for parenteral nutrition. It provides essential and non-essential amino acids to support protein synthesis and energy metabolism, with glycerin serving as a non-glucose caloric source to reduce hyperglycemia. The amino acids are utilized for tissue repair and growth, while glycerin is metabolized via gluconeogenesis and glycolysis.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
Intravenous infusion of 6.4% amino acid solution at 0.8-1.5 g/kg/day (equivalent to 12.5-23.4 mL/kg/day) for protein replenishment; typical adult dose 500-1000 mL/day infused at 1-2 mL/min.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
Not applicable as a single entity; amino acids have varying half-lives (minutes to hours depending on individual amino acid and metabolic state). Clinical context: continuous infusion used for parenteral nutrition; no terminal elimination half-life defined for the mixture.
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Renal elimination of absorbed amino acids and metabolites; minimal biliary/fecal excretion. >90% of infused amino acids are reincorporated into body protein or metabolized; excess nitrogen excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution